Advertisement

Breast Cancer

, 2:79 | Cite as

Prognostic and predictive factors for breast cancer

  • Gary M. Clark
Review Article

Abstract

Prognostic factors can be useful for making decisions about which patients should receive adjuvant therapy, and predictive factors can be used to predict response or lack of response to a particular therapy. We review the standard factors that are available today for primary breast cancer, and we describe some of the new, potential prognostic and predictive factors that are currently under investigation.

Key words

Breast cancer Prognostic factors Predictive factors Survival 

Abbreviations

SBR

Scarff-Bloom-Richardson tumor grade

SEER

Surveillance, Epidemiology, and End Results Program of the National Cancer Institute

ER

Estrogen receptor; PgR:Progesterone receptor

NSABP

National Surgical Adjuvant Breast and Bowel Project

TLI

Thymidine labeling index

BRdU

Bromodeoxyuridine

DNA

eoxyribonucleic acid

CMF

Cyclophosphamide, meth-otrexate, and 5-fluorouracil

CAF

Cyclophosphamide, doxor-ubicin, and 5-fluorouracil

SSCP

Single strand conformation polymorphism

ELISA

Enzyme-linked immunosorbent assay

References

  1. 1).
    Berg JW, Robbins GF: Factors influencing short and long-term survival of breast cancer patients.Surg Gynecol Obstet 122:1311–1316, 1966.PubMedGoogle Scholar
  2. 2).
    Fisher B, Bauer M, Wickerham DL,et al: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer; An NSABP update.Cancer 52:1551–1557, 1983.PubMedCrossRefGoogle Scholar
  3. 3).
    Saez RA, Clark GM, McGuire WL: Prognostic factors in breast cancer.Semin Surg Oncol 5:102–110, 1989.PubMedCrossRefGoogle Scholar
  4. 4).
    Mittra I, MacRae KD: A meta-analysis of reported correlations between prognostic factors in breast cancer; Does axillary lymph node metastasis represent biology or chronology?Eur J Cancer 27:1574–1583, 1991.PubMedGoogle Scholar
  5. 5).
    Adair F, Berg J, Joubert L,et al: Long-term follow-up of breast cancer patients; A 30-year report.Cancer 33:1145–1150, 1974. 6) McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer.N Engl J Med 326:1756-1761, 1992.PubMedCrossRefGoogle Scholar
  6. 7).
    Rosen PP, Groshen S, Saigo PE,et al: Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma; A study of 644 patients with median follow-up of 18 years.J. Clin Oncol 7: 1239–1251, 1989.PubMedGoogle Scholar
  7. 8).
    Rosen PP, Groshen S, Saigo PE,et al: A long-term follow-up study of survival in stage I (TlNlMO)and stage II (T1N1M0) breast carcinoma.J Clin Oncol 7:355–366, 1989.PubMedGoogle Scholar
  8. 9).
    Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer.Br J Cancer 11:359–377, 1957.PubMedGoogle Scholar
  9. 10).
    Scarff RW, Torioni H: Histological Typing of Breast Tumors, WHO, Geneve, ppl3–20, 1968.Google Scholar
  10. 11).
    Fisher ER, Redmond C, Fisher B: Histologic grading of breast cancer.Pathol Ann 15:239–251, 1980.Google Scholar
  11. 12).
    Henson DE: The histological grading of neoplasms.Arch Pathol Lab Med 112:1091–1096, 1988.PubMedGoogle Scholar
  12. 13).
    Knight WA III, Livingston RB, Gregory EJ,et al: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer.Cancer Res 37:4669–4671, 1977.PubMedGoogle Scholar
  13. 14).
    Clark GM, McGuire WL: Steroid receptors and other prognostic factors in primary breast cancer.Semin Oncol 15:20–25, 1988.PubMedGoogle Scholar
  14. 15).
    Nomura Y, Miura S, Koyama H,et al: Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer.Cancer 69: 153–164, 1992.PubMedCrossRefGoogle Scholar
  15. 16).
    Horowitz KB, McGuire WL, Pearson OH,et al: Predicting response to endocrine therapy in human breast cancer; A hypothesis.Science 189:726–727, 1975.CrossRefGoogle Scholar
  16. 17).
    Kinsel LB, Szabo E, Greene GL,et al: Immunocyto-chemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients; Comparison with quantitative biochemical methods.Cancer Res 49:1052–1056, 1989.PubMedGoogle Scholar
  17. 18).
    Berger U, Wilson P, Thethi S,et al: Comparison of an immunocytochemical assay for progesterone receptor with a biochemical method of measurement and immunocytochemical examination of the relationship between progesterone and estrogen receptors.Cancer Res 49:5176–5179, 1989.PubMedGoogle Scholar
  18. 19).
    Foekens JA, Portengen H, van Putten WLJ,et al: Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.Cancer Res 49:5823–5828,1989.PubMedGoogle Scholar
  19. 20).
    Andersen J, Thorpe SM, King W,et al: The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays.Eur J Cancer 26:442–449, 1990.PubMedCrossRefGoogle Scholar
  20. 21).
    Wenger CR, Beardslee S, Owens MA,et al: DNA ploidy, S-phase and steroid receptors in more than 127,000 breast cancer patients.Breast Cancer Res Treat 28:9–20, 1993.PubMedCrossRefGoogle Scholar
  21. 22).
    Hedley DW, Clark GM, Cornelisse CJ,et al: Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast.Cytometry 14:482–485, 1993.PubMedCrossRefGoogle Scholar
  22. 23).
    Remvikos Y, Beuzeboc P, Zajdela A,et al: Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy.J Natl Cancer Inst 81:1383–1387, 1989.PubMedCrossRefGoogle Scholar
  23. 24).
    Dressier LG, Eudey L, Gray R,et al: Prognostic potential of DNA flow cytometry measurement in node-negative breast cancer patients; Preliminary analysis of an Intergroup study (INT0076).J Natl Cancer Inst Monogr 11:167–172, 1992.Google Scholar
  24. 25).
    Zambetti M, Bonadonna G, Valagussa P,et al: Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients.J Natl Cancer Inst Monogr 11:77–83, 1992.PubMedGoogle Scholar
  25. 26).
    Muss HB, Thor AD, Berry DA,et al:c-erbB-2 expression and response to adjuvant therapy in women with node-positive breast cancer.N Engl J Med 330:1260–1266, 1994.PubMedCrossRefGoogle Scholar
  26. 27).
    Legros Y, Lacabanne V, d’Agay MF,et al: Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells.Bull Cancer 80:102–110, 1993.PubMedGoogle Scholar
  27. 28).
    Elledge RM, Clark GM, Fuqua SAW,et al: p53 protein accumulation detected by five different antibodies; Relationship to prognosis and heat shock protein 70 in breast cancer.Cancer Res 54:3752–3757, 1994.PubMedGoogle Scholar
  28. 29).
    Isola J, Visakori T, Holli K,et al: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.J Natl Cancer Inst 84:1109–1114, 1992.PubMedCrossRefGoogle Scholar
  29. 30).
    Allred DC, Clark GM, Elledge R,et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.J Natl Cancer Inst 85:200–206, 1993.PubMedCrossRefGoogle Scholar
  30. 31).
    Silvestrini R, Benini E, Daidone MG,et al: p53 as an independent prognostic marker in lymph node-negative breast cancer patients.J Natl Cancer Inst 85:965–970, 1993.PubMedCrossRefGoogle Scholar
  31. 32).
    Radvin PM, Chamness GC: Thec-erbB-2 protooncogene as a prognostic and predictive marker in breast cancer; A paradigm for the development of other macromolecule markers.Gene 159:19–27, 1995.CrossRefGoogle Scholar
  32. 33).
    Têtu B, Brisson J: Prognostic significance of HER-2/ neu oncoprotein expression in node-positive breast cancer; The influence of the pattern of immunostain-ing and adjuvant therapy.Cancer 73:2359–2365, 1994.PubMedCrossRefGoogle Scholar
  33. 34).
    Allred DC, Clark GM, Tandon AK,et al: UER-2in node-negative breast cancer; Prognostic significance of overexpression influenced by the presence of in situ carcinoma.J Clin Oncol 10:599–605, 1992.PubMedGoogle Scholar
  34. 35).
    Gusterson BA, Gelber RD, Goldhirsch A,et al: Prognostic importance of c-erbB-2 expression in breast cancer; International (Ludwig) Breast Cancer Study Group.J Clin Oncol 10:1049–1056, 1992.PubMedGoogle Scholar
  35. 36).
    Benz CC, Scott GK, Sarup JC,et al: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.Breast Cancer Res Treat 24:85–95, 1992.PubMedCrossRefGoogle Scholar
  36. 37).
    Wright C, Nicholson S, Angus B,et al: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.Br J Cancer 65:118–121, 1992.PubMedGoogle Scholar
  37. 38).
    Ravdin PM: Evaluation of cathepsin D as a prognostic factor in breast cancer.Breast Cancer Res Treat 24:219–226, 1993.PubMedCrossRefGoogle Scholar
  38. 39).
    Tetu Brisson J, Cote C,et al: Prognostic significance of cathepsin-D expression in node-positive breast carcinoma; An immunohistochemical study.Int J Cancer 55:429–435, 1993.PubMedCrossRefGoogle Scholar
  39. 40).
    Johnson MD, Torri JA, Lippman ME,et al: The role of cathepsin D in the invasiveness of human breast cancer cells.Cancer Res 53:873–877, 1993.PubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 1995

Authors and Affiliations

  • Gary M. Clark
    • 1
  1. 1.Division of Medical OncologyUniversity of Texas Health Science Center at San AntonioSan AntonioUSA

Personalised recommendations